Thiazolidinediones and cardiovascular disease: Balancing benefit and harm

Sonal Singh, Yoon K. Loke

Research output: Contribution to journalArticle

Abstract

Cardiovascular disease is the leading cause of mortality among older adults with type II diabetes. The thiazolidinediones (rosiglitazone and pioglitazone) lower blood sugar levels among individuals with type II diabetes. The thiazolidinediones have favourable effects on surrogate markers of cardiovascular disease such as microalbuminuria, carotid intimal thickness, and blood pressure. Emerging evidence from recent randomized clinical trials has confirmed both that thiazolidinediones increase the risk of heart failure, and that rosiglitazone increases the risk of myocardial infarction among those with type II diabetes. Clinicians should avoid thiazolidinediones for older individuals with type II diabetes who are at risk for cardiovascular events as the negative cardiovascular effects of the thiazolidinediones outweigh any potential benefits on surrogate markers.

Original languageEnglish (US)
Pages (from-to)179-183
Number of pages5
JournalGeriatrics and Aging
Volume11
Issue number3
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Thiazolidinediones
rosiglitazone
Cardiovascular Diseases
Type 2 Diabetes Mellitus
pioglitazone
Biomarkers
Tunica Intima
Blood Glucose
Randomized Controlled Trials
Heart Failure
Myocardial Infarction
Blood Pressure
Mortality

Keywords

  • Heart failure
  • Myocardial infarctions
  • Pioglitazone
  • Rosiglitazone
  • Thiazolidinediones

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Thiazolidinediones and cardiovascular disease : Balancing benefit and harm. / Singh, Sonal; Loke, Yoon K.

In: Geriatrics and Aging, Vol. 11, No. 3, 04.2008, p. 179-183.

Research output: Contribution to journalArticle

Singh, Sonal ; Loke, Yoon K. / Thiazolidinediones and cardiovascular disease : Balancing benefit and harm. In: Geriatrics and Aging. 2008 ; Vol. 11, No. 3. pp. 179-183.
@article{0c67ef62b2824d479a6933caa70f308a,
title = "Thiazolidinediones and cardiovascular disease: Balancing benefit and harm",
abstract = "Cardiovascular disease is the leading cause of mortality among older adults with type II diabetes. The thiazolidinediones (rosiglitazone and pioglitazone) lower blood sugar levels among individuals with type II diabetes. The thiazolidinediones have favourable effects on surrogate markers of cardiovascular disease such as microalbuminuria, carotid intimal thickness, and blood pressure. Emerging evidence from recent randomized clinical trials has confirmed both that thiazolidinediones increase the risk of heart failure, and that rosiglitazone increases the risk of myocardial infarction among those with type II diabetes. Clinicians should avoid thiazolidinediones for older individuals with type II diabetes who are at risk for cardiovascular events as the negative cardiovascular effects of the thiazolidinediones outweigh any potential benefits on surrogate markers.",
keywords = "Heart failure, Myocardial infarctions, Pioglitazone, Rosiglitazone, Thiazolidinediones",
author = "Sonal Singh and Loke, {Yoon K.}",
year = "2008",
month = "4",
language = "English (US)",
volume = "11",
pages = "179--183",
journal = "Geriatrics and Aging",
issn = "1488-8408",
publisher = "Geriatrics and Aging",
number = "3",

}

TY - JOUR

T1 - Thiazolidinediones and cardiovascular disease

T2 - Balancing benefit and harm

AU - Singh, Sonal

AU - Loke, Yoon K.

PY - 2008/4

Y1 - 2008/4

N2 - Cardiovascular disease is the leading cause of mortality among older adults with type II diabetes. The thiazolidinediones (rosiglitazone and pioglitazone) lower blood sugar levels among individuals with type II diabetes. The thiazolidinediones have favourable effects on surrogate markers of cardiovascular disease such as microalbuminuria, carotid intimal thickness, and blood pressure. Emerging evidence from recent randomized clinical trials has confirmed both that thiazolidinediones increase the risk of heart failure, and that rosiglitazone increases the risk of myocardial infarction among those with type II diabetes. Clinicians should avoid thiazolidinediones for older individuals with type II diabetes who are at risk for cardiovascular events as the negative cardiovascular effects of the thiazolidinediones outweigh any potential benefits on surrogate markers.

AB - Cardiovascular disease is the leading cause of mortality among older adults with type II diabetes. The thiazolidinediones (rosiglitazone and pioglitazone) lower blood sugar levels among individuals with type II diabetes. The thiazolidinediones have favourable effects on surrogate markers of cardiovascular disease such as microalbuminuria, carotid intimal thickness, and blood pressure. Emerging evidence from recent randomized clinical trials has confirmed both that thiazolidinediones increase the risk of heart failure, and that rosiglitazone increases the risk of myocardial infarction among those with type II diabetes. Clinicians should avoid thiazolidinediones for older individuals with type II diabetes who are at risk for cardiovascular events as the negative cardiovascular effects of the thiazolidinediones outweigh any potential benefits on surrogate markers.

KW - Heart failure

KW - Myocardial infarctions

KW - Pioglitazone

KW - Rosiglitazone

KW - Thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=47249155664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249155664&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:47249155664

VL - 11

SP - 179

EP - 183

JO - Geriatrics and Aging

JF - Geriatrics and Aging

SN - 1488-8408

IS - 3

ER -